These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 16772095)

  • 21. Comparison of an interferon-gamma assay with tuberculin skin testing for detection of tuberculosis (TB) infection in patients with rheumatoid arthritis in a TB-endemic population.
    Ponce de Leon D; Acevedo-Vasquez E; Alvizuri S; Gutierrez C; Cucho M; Alfaro J; Perich R; Sanchez-Torres A; Pastor C; Sanchez-Schwartz C; Medina M; Gamboa R; Ugarte M
    J Rheumatol; 2008 May; 35(5):776-81. PubMed ID: 18398944
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reducing tuberculosis incidence by tuberculin skin testing, preventive treatment, and antiretroviral therapy in an area of low tuberculosis transmission.
    Elzi L; Schlegel M; Weber R; Hirschel B; Cavassini M; Schmid P; Bernasconi E; Rickenbach M; Furrer H;
    Clin Infect Dis; 2007 Jan; 44(1):94-102. PubMed ID: 17143823
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk of tuberculosis in screened subjects without known risk factors for active disease.
    Cook VJ; Hernández-Garduño E; Elwood RK
    Int J Tuberc Lung Dis; 2008 Aug; 12(8):903-8. PubMed ID: 18647449
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of directly observed preventive therapy for latent tuberculosis infection in San Francisco.
    White MC; Gournis E; Kawamura M; Menendez E; Tulsky JP
    Int J Tuberc Lung Dis; 2003 Jan; 7(1):30-5. PubMed ID: 12701832
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acceptance of treatment for latent tuberculosis infection: prospective cohort study in the United States and Canada.
    Colson PW; Hirsch-Moverman Y; Bethel J; Vempaty P; Salcedo K; Wall K; Miranda W; Collins S; Horsburgh CR;
    Int J Tuberc Lung Dis; 2013 Apr; 17(4):473-9. PubMed ID: 23485381
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Completion of therapy for latent tuberculosis in children of different nationalities.
    Powell DA; Perkins L; Wang SH; Hunt G; Ryan-Wenger N
    Pediatr Infect Dis J; 2008 Mar; 27(3):272-4. PubMed ID: 18277917
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Underuse of effective measures to prevent and manage pediatric tuberculosis in the United States.
    Lobato MN; Sun SJ; Moonan PK; Weis SE; Saiman L; Reichard AA; Feja K;
    Arch Pediatr Adolesc Med; 2008 May; 162(5):426-31. PubMed ID: 18458188
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Successful use of rifampicin for Hispanic foreign-born patients with latent tuberculosis infection.
    Haley CA; Stephan S; Vossel LF; Sherfy EA; Laserson KF; Kainer MA
    Int J Tuberc Lung Dis; 2008 Feb; 12(2):160-7. PubMed ID: 18230248
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BCG vaccination and the prevalence of latent tuberculosis infection in an aboriginal population.
    Cook VJ; Kuramoto L; Noertjojo K; Elwood RK; Fitzgerald JM
    Int J Tuberc Lung Dis; 2006 Dec; 10(12):1347-53. PubMed ID: 17167951
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Migrant TB treatment in Haiti resulting in U.S. policy change at Guantánamo Bay, Cuba.
    Bonnlander H
    Bull Pan Am Health Organ; 1996 Sep; 30(3):206-11. PubMed ID: 8897720
    [TBL] [Abstract][Full Text] [Related]  

  • 31. QuantiFERON-TB Gold test in the identification of latent tuberculosis infection in immigrants.
    Carvalho AC; Pezzoli MC; El-Hamad I; Arce P; Bigoni S; Scarcella C; Indelicato AM; Scolari C; Carosi G; Matteelli A
    J Infect; 2007 Aug; 55(2):164-8. PubMed ID: 17428542
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of the QuantiFERON-TB Gold test to confirm latent tuberculosis infection in a Canadian tuberculosis clinic.
    Kunimoto D; Der E; Beckon A; Thomas L; Egedahl M; Beatch A; Williams G; Tyrrell G; Ahmed R; Brown N; Long R
    Int J Tuberc Lung Dis; 2009 Jun; 13(6):726-30. PubMed ID: 19460248
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Incidence of and factors for non-compliance to antituberculous treatment].
    Cáceres Fde M; Orozco LC
    Biomedica; 2007 Dec; 27(4):498-504. PubMed ID: 18320117
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predicting completion of treatment among foreign-born adolescents treated for latent tuberculosis infection in Los Angeles.
    Coly A; Morisky D
    Int J Tuberc Lung Dis; 2004 Jun; 8(6):703-10. PubMed ID: 15182139
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Recommendations for the diagnosis and treatment of latent and active tuberculosis in patients with inflammatory joint diseases treated with tumour necrosis factor alpha inhibitors].
    Fonseca JE; Lucas H; Canhão H; Duarte R; Santos MJ; Villar M; Faustino A; Raymundo E; ;
    Acta Reumatol Port; 2006; 31(3):237-45. PubMed ID: 17094335
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tuberculin skin test size and risk of tuberculosis development: a large population-based study in contacts.
    Morán-Mendoza O; Marion SA; Elwood K; Patrick DM; FitzGerald JM
    Int J Tuberc Lung Dis; 2007 Sep; 11(9):1014-20. PubMed ID: 17705981
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effectiveness of a 9-month regimen of isoniazid alone versus 3- and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized study.
    Spyridis NP; Spyridis PG; Gelesme A; Sypsa V; Valianatou M; Metsou F; Gourgiotis D; Tsolia MN
    Clin Infect Dis; 2007 Sep; 45(6):715-22. PubMed ID: 17712755
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Guidelines for the diagnosis and treatment of latent tuberculosis infection and active tuberculosis in patients with inflammatory joint diseases proposed for treatment with tumour necrosis factor alpha antagonist drugs].
    Fonseca JE; Lucas H; Canhão H; Duarte R; Santos MJ; Villar M; Faustino A; Raymundo E; ;
    Rev Port Pneumol; 2006; 12(5):603-13. PubMed ID: 17117328
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Usefulness of enzyme-linked immunospot assay (Elispot) compared to tuberculin skin testing for latent tuberculosis screening in rheumatic patients scheduled for anti-tumor necrosis factor treatment.
    Vassilopoulos D; Stamoulis N; Hadziyannis E; Archimandritis AJ
    J Rheumatol; 2008 Jul; 35(7):1271-6. PubMed ID: 18381793
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Age-specific cut-offs for the tuberculin skin test to detect latent tuberculosis in BCG-vaccinated children.
    Chan PC; Chang LY; Wu YC; Lu CY; Kuo HS; Lee CY; Huang LM; Chen CJ
    Int J Tuberc Lung Dis; 2008 Dec; 12(12):1401-6. PubMed ID: 19017449
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.